Search results for "Postprandial period"

showing 8 items of 48 documents

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients Wi…

2018

Objective— Treatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist, has been shown to reduce postprandial lipidemia, an important feature of diabetic dyslipidemia. However, the underlying mechanisms for this effect remain unknown. This prompted us to study the effect of liraglutide on the metabolism of ApoB48 (apolipoprotein B48). Approach and Results— We performed an in vivo kinetic study with stable isotopes (D 8 -valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d). We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides an…

MaleApolipoprotein B-48Agonistmedicine.medical_specialtymedicine.drug_classhyperlipidemiasGene Expression030209 endocrinology & metabolism030204 cardiovascular system & hematologypatients03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusChylomicronsHyperlipidemiaAnimalsHumansMedicineDiacylglycerol O-AcyltransferaseProspective StudiesTriglycerides[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMice Inbred BALB Cliraglutidebusiness.industryLiraglutideCatabolismType 2 Diabetes Mellitus[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismPostprandial Periodmedicine.diseaseLipoprotein LipaseJejunumEndocrinologyPostprandialAdipose TissueDiabetes Mellitus Type 2kineticsdiabetes mellitusFemaleApolipoprotein B-48Carrier ProteinsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.

2007

Objective— Apolipoprotein A5 ( APOA5 ) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy. Methods and Results— We examined the association between tag SNPs (−1131T>C and 56C>G) at APOA5 and TG and HDL-C response to fenofibrate and a postprandial lipid challenge in 791 men and women participating in the GOLDN study. After 3-week drug treatment, APOA5 56G carriers displayed significant decrease in TG ( P =0.006), and increase in HDL-C ( P =0.002) levels relative to their basal values in the fasting state when compared with noncarriers (a TG re…

MaleTime FactorsApolipoprotein BAdministration Oralchemistry.chemical_compoundFenofibrateGene FrequencyApolipoprotein a5Hypolipidemic AgentsAged 80 and overFenofibratebiologyMiddle AgedPostprandial PeriodPostprandialTreatment OutcomeArea Under CurveFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyGuanineAdolescentGenotypeSingle-nucleotide polymorphismHyperlipidemiasPolymorphism Single NucleotideCytosineInternal medicinemedicineHumansParticle SizeApolipoproteins ATriglyceridesAgedTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLDrug interactionLipid MetabolismDietary FatsUnited StatesEndocrinologychemistryApolipoprotein A-Vbiology.proteinbusinessThymineArteriosclerosis, thrombosis, and vascular biology
researchProduct

Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes

2010

Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbA1c] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased …

Malehigh-density lipoproteinsmedicine.medical_specialtyType 2 diabetes030204 cardiovascular system & hematologysizeStatistics NonparametricRosiglitazone03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicinelow-density lipoproteinsHumansHypoglycemic AgentsProspective Studies030212 general & internal medicineGlycated Hemoglobindiabetesbusiness.industryFastingMiddle AgedPostprandial Periodmedicine.diseaseLipids3. Good healthLipoproteins LDLPostprandialEndocrinologyDiabetes Mellitus Type 2FemaleThiazolidinedioneslipids (amino acids peptides and proteins)HemoglobinsubclassesLipoproteins HDLCardiology and Cardiovascular MedicineRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugLipoprotein
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2…

2008

To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes.Nine Type 2 diabetic patients (age 61 +/- 10 years, body mass index 30 +/- 5 kg/m(2), glycosylated hemoglobin [HbA1c] 7.5 +/- 0.5%) were randomized in a crossover trial to rosiglitazone 4 mg b.i.d. or pioglitazone 45 mg/day for 12 weeks with an 8-week wash-out period. LDL size and subclasses were determined by non-denaturing polyacrylamide gradient gel electrophoresis. A standardized breakfast was served and variables were assessed after 3 and 6 h.HbA1c, insulin sensitivity (as assessed by the homeostasis model assessment) and…

Malemedicine.medical_specialtyType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)Prospective StudiesTriglyceridesPharmacologyGlycated HemoglobinCross-Over StudiesTriglyceridePioglitazoneCholesterolbusiness.industryGeneral MedicineCholesterol LDLFastingGlucose Tolerance TestMiddle Agedmedicine.diseasePostprandial PeriodLipoproteins LDLPostprandialEndocrinologychemistryDiabetes Mellitus Type 2Low-density lipoproteindense LDL diabetes LDL size pioglitazone postprandial rosiglitazoneElectrophoresis Polyacrylamide GelFemaleThiazolidinedionesbusinessRosiglitazonePioglitazonemedicine.drug
researchProduct

Small bowel motility: relationship between smooth muscle contraction and electroenterogram signal.

2000

A study is made to correlate the electrical and mechanical activity of the smooth muscle of the small bowel. Bioelectrical signal recording from the intestinal serosa (electroenterogram) comprises a slow wave (SW) and spike burst (SB), though only the latter reflects intestinal pressure. The electroenterogram and smooth muscle pressure are simultaneously recorded in the canine small bowel. Spectral and time series analysis of the electroenterogram are performed to establish those electrical parameters that best reflect intestinal pressure. The results reveal an underlying correlation between the estimated parameters of electrical activity and smooth muscle pressure. In addition, parameters …

PeriodicityDuodenumManometryBiomedical EngineeringBiophysicsContext (language use)ElectromyographySignalDogsIntestine SmallmedicinePressureAnimalsBiosignalmedicine.diagnostic_testElectrical impedance myographyChemistryElectromyographyMyographySpectral densityMuscle SmoothSignal Processing Computer-AssistedAnatomySmooth muscle contractionFastingPostprandial PeriodJejunumLinear Modelsmedicine.symptomGastrointestinal MotilityBiomedical engineeringMuscle contractionMuscle ContractionMedical engineeringphysics
researchProduct

Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles.

2005

It is known that sphingomyelin (SM) content is higher in apolipoprotein B-containing particles (BLps) than in high density lipoproteins and that BLp levels, including chylomicrons and their remnant particles, are positively related to atherosclerosis. To evaluate the relationship between serum SM and postprandial remnant particle levels, we determined SM, triglyceride (TG), and cholesterol levels in serum and in remnant-like particles (RLPs) before and 3, 5, 7, and 10 h after a high-fat meal in 31 healthy subjects. We found that serum SM, like serum TG, was increased to its maximum 3 h after fat loading and then gradually decreased to basal levels after 10 h. More important, we determined t…

medicine.medical_specialtyTime FactorsApolipoprotein BArteriosclerosisQD415-436Biochemistrychemistry.chemical_compoundEndocrinologylipidInternal medicineChylomicronsmedicineHumansTriglyceridesApolipoproteins BbiologyTriglycerideCholesterollipoproteinCholesterol HDLCell BiologyArteriosclerosismedicine.diseasePostprandial PeriodSphingomyelinsEndocrinologyPostprandialCholesterolchemistrybiology.proteinatherosclerosisSphingomyelinLipoproteins HDLBiomarkersChylomicronLipoproteinJournal of lipid research
researchProduct

Postprandial triglyceridaemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects

2020

Background Obesity is associated with high cardiovascular risk. Postprandial lipidaemia has been associated with cardiovascular disease risk. Our aim was to identify whether anthropometric parameters, insulin resistance (IR) and/or fasting plasma triglycerides may determine postprandial changes in lipoprotein concentrations in abdominal and morbid obese subjects. Methods We have studied 20 non-diabetic, normolipidaemic subjects with abdominal obesity, 20 morbid obese subjects and 20 healthy individuals, that have similar age and gender. In all of them a standardised oral fat load test (OFLT) with unsaturated fat was performed. Results During the OFLT, the postprandial triglycerides response…

medicine.medical_specialtyWaist030204 cardiovascular system & hematologyGastroenterologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansInsulin030212 general & internal medicineTriglyceridesAbdominal obesitybusiness.industryUnsaturated fatGeneral MedicinePostprandial Periodmedicine.diseaseObesityObesity MorbidPostprandialchemistryObese subjectsInsulin Resistancemedicine.symptombusinessLipoproteinInternational Journal of Clinical Practice
researchProduct